Unlike pharma , it is not very common to see companies taking up off patented molecules, may by this is mostly due to small opportunity size, so investment in making a copy cat generic needs more investment. The easiest option is buy the license the innovator with technical know how and produce the molecules. Anyone has any views on this ?
Subscribe To Our Free Newsletter |